Lupin Limited (BOM:500257)
2,178.00
+3.00 (0.14%)
At close: Aug 31, 2026
Lupin Revenue
Lupin had revenue of 82.77B INR in the quarter ending June 30, 2026, with 32.04% growth. This brings the company's revenue in the last twelve months to 299.67B, up 28.19% year-over-year. In the fiscal year ending March 31, 2026, Lupin had annual revenue of 279.58B with 23.12% growth.
Revenue (ttm)
299.67B
Revenue Growth
+28.19%
P/S Ratio
3.32
Revenue / Employee
11.52M
Employees
26,021
Market Cap
995.86B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 279.58B | 52.50B | 23.12% |
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 331.19B |
| Torrent Pharmaceuticals | 157.23B |
| Jubilant Pharmova | 86.08B |
| Abbott India | 70.04B |
| Granules India | 56.32B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 39.55B |
| Viyash Scientific | 35.75B |
Lupin News
- 13 days ago - Lupin Secures FDA Approval For Pitolisant Tablets, Generic Of WAKIX; Expects Launch In 2030 - Nasdaq
- 24 days ago - Lupin Transcript: Q1 26/27 - Transcripts
- 24 days ago - Lupin Quarterly report: Q1 2027 - Filings
- 24 days ago - Lupin Slides: Q1 2027 - Filings
- 5 weeks ago - Lupin Transfers Two Oncology Assets To Kaveri Therapeutics - Nasdaq
- 2 months ago - Lupin receives EIR from U.S. FDA for Somerset facility with VAI classification - Business Upturn
- 2 months ago - Lupin receives EMA approval for NaMuscla expansion for paediatric use - Business Upturn
- 2 months ago - Lupin Gets Tentative FDA Nod For Enzalutamide Tablets - Nasdaq